-transparent.png){kind=logo}
The pharmacokinetics of pramiracetam was assessed using an HPLC method after oral administration of two different formulations of 600 mg (a solution and a tablet) of pramiracetam to 11 fasting volunteers. The mean kinetic parameters were: t1 = 4.7 +/- 2.4 - 4.3 +/- 2.2 h, AUC = 57.6 +/- 43.6 - 47.2 +/- 33.9 micrograms h/ml, Cmax = 6.80 +/- 3.2 - 5.80 +/- 3.3 micrograms/ml for the solution and the tablet respectively. The plasma profile of pramiracetam proved to be not highly affected by the formulation, only that the absorption rate was faster after oral administration of the drug in solution than after administration as a tablet. The half-life was very variable between subjects [2-8 hours], but less variable within subjects and it was unaffected by the formulation.
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
January 1985,
Journal of clinical pharmacology,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
October 1986,
British journal of clinical pharmacology,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
December 1992,
Journal of pharmaceutical sciences,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
May 2016,
International journal of clinical pharmacology and therapeutics,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
April 1986,
European journal of clinical microbiology,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
January 1997,
The American journal of tropical medicine and hygiene,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
August 1984,
European journal of clinical microbiology,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
September 1993,
Journal of pharmaceutical sciences,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
September 1994,
Journal of pharmaceutical sciences,
A Auteri, and
P Blardi, and
G Celasco, and
G Segre, and
R Urso
January 1989,
Fundamental & clinical pharmacology,
